ArticleScientific reports2025
New nanomanufacturing strategy through bioinspired design, for promising treatment of Parkinson's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study attempts to develop a new nanomanufacturing strategy for Parkinson's disease using natural biodegradable components (chitosan, albumin, and dopamine) that can penetrate the blood-brain barrier (BBB) due to biocompatibility, biodegradability, targeted delivery, and controlled drug release. It was prepared, thoroughly optimized and characterized using various biophysical and chemical techniques. Results showed that the nanomanufactured system (molar ratio of 1:0.25:0.5 and particle size range: 38-190 nm) exhibited a zeta potential of + 73 mV facilitating efficient pentration of BBB through an adsorption mechanism with the cell membrane's negative charges. The particle size of the nanomanufactured system and spherical nanoparticle clusters indicated its ability to enhance dopamine delivery to brain tissues. Encapsulation efficiency was measured at 74.31 ± 0.29 with dopamine release faster at pH 5.4 and sustained release over 96 h in both acidic media (pH 5.4) or physiological conditions (pH 7.4). Cytotoxicity studies showed a degradation rate in normal cells that never exceeded 20% and the nanomanufactured system exhibited low half-maximal inhibitory concentration (IC50) values, indicating low cytotoxicity. Albumin plays a vital and distinct role in stimulating normal cells and enhancing the transport system to the target via an adsorptive-mediated endocytosis pathway. The electron microscopy images depict distrution of heterogeneous nanoparticles, with sizes ranged from 36.86 nm to 190.3 nm and a mean average diameter of 108.1 nm. The average particle size of the nanosystem was 49.4 ± 9.9 nm, with a Polydispersity Index (PI) of 0.494. The loading efficiency was 14.78 ± 0.37% and the encapsulation efficiency was 74.31 ± 0.29%. This nanomanufactured system holds significant promise for improving Parkinson's disease treatment by enabling targeted and efficient drug delivery to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.